SLC46A1
MOLECULAR TARGETsolute carrier family 46 member 1
SLC46A1 (solute carrier family 46 member 1) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SLC46A1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | methotrexate | 6.00 | 404 |
| 2 | raltitrexed | 3.58 | 35 |
| 3 | Pemetrexed | 3.04 | 20 |
| 4 | pralatrexate | 2.08 | 7 |
| 5 | Methotrexate | 1.10 | 2 |
| 6 | Leucovorin | 0.69 | 1 |
About SLC46A1 as a Drug Target
SLC46A1 (solute carrier family 46 member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented SLC46A1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SLC46A1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.